Amarin Corp Plc (AMRN)

[Biobillionair]

MedRes-

You’re right—that would certainly make an Advisory Committee (AC) meeting being held to discuss the Vascepa efficacy supplement a bad omen, signifying that FDA may consider the purported efficacy of Vascepa from the REDUCE-IT study as dubious.

I 100% agree with you. This is why I've hounded the FDA and Amarin since October 16th 2013. If the FDA wants to lie down on the tracks while the freight train cruises at 80 MPH so be it...this train is not slowing with ADA SOC, ICER report and NEJM report 9-2018.

If you think your 3 sham Citizen Petitions is slowing this train down you deserve ever bit of consciousness before it goes dark forever.

BB

(life of this post 3 minutes)